ClinicalTrials.gg
RecruitingNCT07916480INTEGUMENT 3Updated Nov 6, 2026

Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis

A Phase 3 interventional study of Roflumilast Cream 0.3% and Vehicle Cream in Atopic Dermatitis, Atopic Dermatitis (AD) and Atopic Dermatitis (Eczema), sponsored by Arcutis Biotherapeutics, Inc.. Recruiting at 4 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Arcutis Biotherapeutics, Inc. · Phase 3, Interventional, and Treatment

Updated Nov 6, 2026Now RecruitingStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
415
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing roflumilast in Dermatitis, Atopic — 4 open to participants now, 4 under way, 1 of them phase 3. Roflumilast · Dermatitis, Atopic.

Planned enrollment
5th of 13
415 · median 136
Started
2026
with 2 others
Phase 3
6 of 13
1 open now
Registered
13th of 13
by date
Lead sponsor
8 of 13
Arcutis Biotherapeutics, Inc.

Among the 13 studies testing roflumilast in Dermatitis, Atopic, this one is the 5th largest by planned enrollment, is one of 3 that started in 2026, is one of 6 in phase 3, and was the 13th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 13 studies testing roflumilast in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing roflumilast in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This Phase 3 study is designed to evaluate the efficacy and safety of once-daily roflumilast cream 0.3% in children, adolescents, and adults with moderate to severe atopic dermatitis. Approximately 415 participants will be randomized in a 2:1 ratio to receive roflumilast cream 0.3% or matching vehicle cream during a 4-week double-blind, vehicle-controlled treatment period.

Following completion of the double-blind treatment period, all participants will enter a 48-week open-label extension and receive roflumilast cream 0.3%. The study will assess the efficacy of roflumilast cream 0.3% in improving signs and symptoms of atopic dermatitis and evaluate its long-term safety and tolerability through Week 52.

Read the detailed description

This Phase 3, multicenter, randomized, double-blind, vehicle-controlled study is designed to evaluate the efficacy, safety, and tolerability of once-daily roflumilast cream 0.3% in children, adolescents, and adults with moderate to severe atopic dermatitis.

Approximately 415 participants aged 6 years and older with moderate to severe atopic dermatitis will be randomized in a 2:1 ratio to receive either roflumilast cream 0.3% or matching vehicle cream once daily for 4 weeks during the double-blind treatment period.

The primary objective of the study is to evaluate the efficacy of roflumilast cream 0.3% compared with vehicle cream at Week 4. Secondary objectives include evaluation of additional efficacy measures related to the signs and symptoms of atopic dermatitis.

Participants who complete the double-blind treatment period will be eligible to enter a 48-week open-label extension period, during which all participants will receive once-daily roflumilast cream 0.3%. The open-label extension is designed to evaluate the long-term safety, tolerability, and efficacy of roflumilast cream 0.3% through Week 52.

Safety assessments will include adverse events, local tolerability, clinical laboratory evaluations, vital signs, physical examinations, and other protocol-specified safety assessments.

03

Conditions studied

  • Atopic Dermatitis
  • Atopic Dermatitis (AD)
  • Atopic Dermatitis (Eczema)

Keywords

  • Atopic Dermatitis
  • Eczema
  • Roflumilast
  • Roflumilast Cream
  • Phosphodiesterase 4 Inhibitor
  • PDE4 Inhibitor
  • Moderate Atopic Dermatitis
  • Severe Atopic Dermatitis
  • Pruritus
  • Inflammatory Skin Disease
  • Topical Therapy
  • Dermatology
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 6 years and older.
  2. Clinical diagnosis of moderate to severe atopic dermatitis.
  3. vIGA-AD score of 3 (Moderate) or 4 (Severe) at baseline.
  4. EASI score ≥5 at baseline.
  5. Atopic dermatitis involvement of ≥3% and ≤30% body surface area.
  6. Able and willing to comply with study procedures.
  7. Participant or parent/legal guardian able to provide /assent.

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled medical conditions that could interfere with study participation.
  2. Skin disorders that may confound study assessments.
  3. Active infection requiring systemic treatment.
  4. Known to roflumilast or formulation components.
  5. Use of prohibited medications within protocol-defined .
  6. Pregnant or breastfeeding participants.
  7. Participation in another interventional clinical trial within the protocol-defined timeframe.
  8. Any condition that, in the investigator's opinion, would make participation unsafe or interfere with study results.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
415 participants (estimated)

Study arms

  • Placebo comparator
    Vehicle Cream

    Participants will apply matching vehicle cream once daily during the 4-week double-blind treatment period.

    Drug: Vehicle Cream

  • Experimental
    Roflumilast Cream 0.3%

    Participants will apply roflumilast cream 0.3% once daily during the 4-week double-blind treatment period.

    Drug: Roflumilast Cream 0.3%

Interventions

  • Roflumilast cream 0.3% administered topically once daily to affected areas during the 4-week double-blind treatment period. Participants may continue treatment with roflumilast cream 0.3% during the 48-week open-label extension.

  • DrugVehicle Cream

    Matching vehicle cream administered topically once daily to affected areas during the 4-week double-blind treatment period. Participants will receive roflumilast cream 0.3% during the open-label extension phase.

06

What researchers measure

Primary outcomes

  1. Achievement of vIGA-AD Success at Week 4

    vIGA-AD Success is defined as achieving a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of Clear (0) or Almost Clear (1) with at least a 2-grade improvement from Baseline.

    Time frame: Week 4

Secondary outcomes

  1. Achievement of at least a 75% reduction in the Eczema Area and Severity Index (EASI-75)

    EASI-75 is defined as achieving at least a 75% reduction from Baseline in Eczema Area and Severity Index (EASI) score.

    Time frame: Week 4

  2. In participants ≥12 years old with Baseline Itch-NRS ≥ 4, achievement of at least a 4-point reduction on the Itch-NRS

    In participants aged ≥12 years and older with a Baseline Itch Numeric Rating Scale (Itch-NRS) score of 4 or greater who achieve at least a 4-point reduction from Baseline in the Itch-NRS score at Week 4. The Itch-NRS is an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable), with higher scores indicating greater itch severity.

    Time frame: Week 4

07

Study locations

4 of 4 sites recruiting
  • Arcutis Site 324
    Birmingham, Alabama 35244, United States
    Recruiting
  • Arcutis Site 337
    Bryant, Arkansas 72022, United States
    Recruiting
  • Arcutis Site 321
    Miami Lakes, Florida 33014, United States
    Recruiting
  • Arcutis Site 320
    Chicago, Illinois 60523, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Apr 2028, 17 months after the start.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 17 months is close to that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2026
First posted
Nov 4, 2026
StartActual
Oct 30, 2026
Primary completionEst.
Apr 27, 2028
CompletionEst.
Mar 28, 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
4 sites added, 1 site removed
Show 4 added (4 United States)
  • Arcutis Site 324 · Birmingham, United States
  • Arcutis Site 337 · Bryant, United States
  • Arcutis Site 321 · Miami Lakes, United States
  • Arcutis Site 320 · Chicago, United States
Show 1 removed
  • Arcutis Site 1 · Chicago, United States
Nov 6, 2026
Start date
Oct 20, 2026→Oct 30, 2026 (actual)
Nov 6, 2026
Registered
First appeared on the registry
Nov 4, 2026
Show all 2 updates
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    4 sites added, 1 site removed
    Show 4 added (4 United States)
    • Arcutis Site 324 · Birmingham, United States
    • Arcutis Site 337 · Bryant, United States
    • Arcutis Site 321 · Miami Lakes, United States
    • Arcutis Site 320 · Chicago, United States
    Show 1 removed
    • Arcutis Site 1 · Chicago, United States
    Start date Oct 20, 2026→Oct 30, 2026 (now actual)
    + 1 other change: verification date
  2. Nov 4, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07916480
Responsible party
Sponsor
First posted
Nov 4, 2026
Start date
Oct 30, 2026
Primary completion
Apr 27, 2028 (estimated)
Completion
Mar 28, 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Arcutis Medical Information
Contact
medinfo@arcutis.com
1-844-692-6729

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion